Abstract
The development of angiotensin-converting enzyme inhibitors and selective angiotensin type 1 (AT1)- receptor antagonists has provided new insights into understanding the mechanism of the renin-angiotensin system (RAS) in the pathophysiology of cardiovascular disease. There is good evidence from meta-analyses that shows that inhibition of the RAS achieves organ protection features that go beyond blood pressure control. Candesartan cilexetil, a new angiotensin II receptor antagonist, is characterised by its tight binding to and slow dissociation from the AT1receptor, and high antagonistic potency, resulting in long-lasting antagonistic effects. It is anticipated that these pharmacological characteristics may bring additional benefits to patients, not only for the management of essential hypertension but also for the management of end-organ damage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Unger, T., Azizi, M. & Belz, G. Blocking the tissue renin-angiotensin system: the future cornerstone of therapy. J Hum Hypertens 14 (Suppl 2), S23–S31 (2000). https://doi.org/10.1038/sj.jhh.1001070
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001070
Keywords
This article is cited by
-
Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial
Journal of Human Hypertension (2005)
-
Medical treatment of diabetic retinopathy
Eye (2003)